Front Row: SABCS 2025 Insights with Dr. Francisco Esteva

Front Row: SABCS 2025 Insights with Dr. Francisco Esteva

Join host Victoria Goldberg and Dr. Francisco Esteva as they break down the groundbreaking research from the San Antonio Breast Cancer Symposium 2025. Discover the latest advances in metastatic breast cancer treatment, including new first-line therapies for HER2-positive disease with 40-month progression-free survival, oral SERDs revolutionizing hormone receptor-positive treatment, and antibody drug conjugates transforming triple-negative breast cancer care. Dr. Esteva shares expert insights on brain metastasis prevention, liquid biopsy-guided therapy switching, and how artificial intelligence is reshaping oncology. Whether you're a patient, caregiver, or healthcare professional, this episode offers hope and practical information about the cutting-edge treatments available in 2026.

Read More
Fighting for Patients: Dr. Rebecca Shatsky on Insurance, Burnout, and Hope in MBC

Fighting for Patients: Dr. Rebecca Shatsky on Insurance, Burnout, and Hope in MBC

Dr. Rebecca Shatsky, Director of Breast Medical Oncology at UC San Diego, shares her experiences fighting for patients with breast cancer. In this episode, Dr. Shatsky discusses the growing challenges clinicians face—from insurance denials and funding cuts to the emotional toll of burnout and the spread of cancer misinformation.

Hear real stories about advocating for life-saving treatments, navigating the complexities of clinical trials, and the importance of patient empowerment. Dr. Shatsky also offers hope, highlighting the latest breakthroughs in metastatic breast cancer research and the progress being made in treatment options.

Whether you’re a patient, caregiver, or healthcare professional, this episode delivers candid insights, practical advice, and a message of resilience and hope in the face of adversity.

Read More
Live Chat: SERD Surge with Dr. Sherry Shen

Live Chat: SERD Surge with Dr. Sherry Shen

Host Victoria, with Dr. Sherry Shen and co-host Ellen, delivers a concise, patient-focused overview of oral SERDs in HR+ metastatic breast cancer—covering ESR1 mutations, key trials (evERA, SERENA‑6), FDA‑approved agents, side-effect management, and treatment implications. This is the first episode in our Live Chats series. Bonus clip: Rebecca Shatsky, MD, previews the evERA trial and her excitement about combining capivasertib with oral SERDs.

Read More